Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630485 | 0.82 | PARP1 (1.00) | PARP1 | |
| Hydrochloric Acid SCHEMBL7358627 | 0.81 | PARP1 (0.97) | PARP1 | |
| SCHEMBL1413261 | 0.79 | PARP1 (0.66) | PARP1LMNARXFP1PRMT5 | |
| SCHEMBL1413262 | 0.79 | PARP1 (0.66) | PARP1LMNARXFP1PRMT5 | |
| SCHEMBL30831905 | 0.79 | PARP1 (0.66) | PARP1LMNARXFP1PRMT5 | |
| SCHEMBL1413263 | 0.79 | PARP1 (0.57) | PARP1LMNARXFP1PRMT5BRD4 | |
| Hydrochloric Acid SCHEMBL28102418 | 0.76 | PARP1 (0.62) | PARP1LMNARXFP1PRMT5BRD4 | |
| SCHEMBL453514 | 0.76 | PARP1 (0.72) | PARP1RXFP1 | |
| SCHEMBL24344828 | 0.75 | PARP1 (0.60) | PARP1RXFP1BRD4 | |
| Hydrochloric Acid SCHEMBL22165594 | 0.75 | PARP1 (0.70) | PARP1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951065-B2 | Benzimidazole and imadazopyridine carboximidamide compounds | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3294732-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | Gilead Sciences, Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| WO-2016186967-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | GILEAD SCIENCES, INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | IDO1, IDO2, INMT | PARP1 566/4885LMNA 2375/4885RXFP1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.